|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Interferon Sciences |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002012 |
Purpose
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV+, AIDS-related complex (ARC) patients.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Interferon alfa-n3 |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind |
| Official Title: | Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 45 days of study entry:
Contacts and Locations
More Information
| Study ID Numbers: | 069A, 90-151ME |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002012 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Acquired Immunodeficiency Syndrome AIDS-Related Complex Interferon Type I, Recombinant |
|
Interferon-alpha Sexually Transmitted Diseases, Viral Interferon Type I, Recombinant Immunologic Factors Acquired Immunodeficiency Syndrome Interferons AIDS-Related Complex Angiogenesis Inhibitors |
Antiviral Agents Immunologic Deficiency Syndromes Virus Diseases HIV Infections Sexually Transmitted Diseases Interferon Alfa-2a Retroviridae Infections |
|
Anti-Infective Agents Sexually Transmitted Diseases, Viral Interferon Type I, Recombinant Slow Virus Diseases Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Infection Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Retroviridae Infections Interferon-alpha RNA Virus Infections |
Immune System Diseases Growth Substances Acquired Immunodeficiency Syndrome Interferons Antiviral Agents Angiogenesis Inhibitors Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Interferon Alfa-2a |